Avalo Therapeutics (AVTX) Assets Average (2016 - 2025)
Avalo Therapeutics (AVTX) has disclosed Assets Average for 11 consecutive years, with $125.8 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Assets Average rose 21.73% year-over-year to $125.8 million, compared with a TTM value of $125.8 million through Sep 2025, up 21.73%, and an annual FY2024 reading of $85.9 million, up 215.9% over the prior year.
- Assets Average was $125.8 million for Q3 2025 at Avalo Therapeutics, down from $132.6 million in the prior quarter.
- Across five years, Assets Average topped out at $144.6 million in Q1 2025 and bottomed at $25.1 million in Q4 2023.
- Average Assets Average over 5 years is $74.1 million, with a median of $71.1 million recorded in 2022.
- The sharpest move saw Assets Average plummeted 60.18% in 2022, then skyrocketed 395.77% in 2024.
- Year by year, Assets Average stood at $87.8 million in 2021, then tumbled by 60.18% to $35.0 million in 2022, then dropped by 28.11% to $25.1 million in 2023, then soared by 395.77% to $124.6 million in 2024, then grew by 1.0% to $125.8 million in 2025.
- Business Quant data shows Assets Average for AVTX at $125.8 million in Q3 2025, $132.6 million in Q2 2025, and $144.6 million in Q1 2025.